Base Year
Historical Year
Forecast Year
The Wilson’s disease market size was valued at USD 1457.5 million in 2024, driven by the rising research and development activities in drug development across the major markets. The market is expected to grow at a CAGR of 3.2% during the forecast period of 2025-2034, with the values likely to rise from USD 1498.9 million in 2025 to USD 1926.6 million by 2034.
Wilson’s disease is a rare genetic condition that leads to copper level build up in several body organs, particularly, brain, eyes, and liver. Major symptoms include yellowing of skin and eyes, occurrence of golden-brown or copper-colored rings around the irises of the eyes (Kayser-Fleischer rings), along with tiredness, loss of appetite, fluid buildup in legs and stomach area. It is treated via medications and surgery in case of extreme cases.
Wilson’s disease has been treated via medications that constitute chelating agents (medicines that remove copper from the body). Penicillamine (Cupramine, Depen) and trientine (Syprine) are two commonly prescribed medications that help remove excess copper from the body. Zinc is another frequent medication that blocks copper absorption in intestines.
Wilson’s disease market demand is further fueled by the rising advancements in gene therapies. In September 2023, UC Davis Health researchers infused the first ever gene therapy in an affected patient. The clinical trial for Wilson’s disease called CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment. It is an adeno-associated virus gene therapy that restores the function of ATP7B, that improves copper metabolism and distribution in the body.
With increasing technical advances in the medical ecosystem, scientists have been looking into finding ways to effectively devise better diagnostic methods that identify the illness at an early stage. Similarly, a better understanding of human physiology, along with hefty investments made by public and private institutions, is also poised to fuel the Wilson’s disease market value in upcoming years.
Market Breakup by Diagnosis Method
Market Breakup by Treatment Type
Market Breakup by Mode of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
The United States is anticipated to dominate the Wilson’s disease market share in the forecast period. The market size can be accredited to increasing mergers and acquisitions in the region to foster better inventions for patient outcomes. Several companies are growing their product portfolios to meet the high demand for patient therapeutics.
Europe is another significant market with a robust healthcare and research infrastructure that aids market growth. The presence of prominent research and academic institutions along with leading healthcare companies also fuels market value.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnosis Method |
|
| Breakup by Treatment Type |
|
| Breakup by Mode of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 1457.5 million in 2024, driven by increasing research and development activities in drug development across the major markets.
The market is anticipated to grow at a CAGR of 3.2% during the forecast period of 2025-2034, likely to reach a market value of USD 1926.6 million by 2034.
The market demand is driven by the rising expenditure on medical research and development to develop better treatment methods for the disease.
The major market trend involves the application of gene therapies as a treatment alternative. In September 2023, results from a clinical trial called, CYPRUS2+ displayed positive results for UX701, the investigational gene therapy treatment for Wilson’s disease.
The major regions of the market include the United States, Japan, EU-4 which is segmented into Germany, France, Italy, Spain, and the United Kingdom.
The diagnosis methods include blood and urine test, eye exam, biopsy, and genetic testing.
The treatment types can be categorised into medications (penicillamine trientine dihydrocholoride and trientine tetrahydrochoride) and surgery.
The modes of administration can be divided into injectable and oral, among others.
The end users can be divided into hospitals, homecare, and specialty clinics, among other others.
The distribution channels can be divided into hospital pharmacies, retail pharmacies, and online pharmacies.
Key players involved in the market are Teva Pharmaceutical, ANI Pharmaceuticals, Bausch Health, DR. REDDY’S LABORATORIES LTD, Breckenridge Pharmaceutical, Inc., Par pharmaceutical, Lupin, Panacea Biotech Ltd., Apotex, Navinta LLC, Amneal Pharmaceuticals LLC., Meda Pharmaceuticals, Ipsen Pharma, Noblepharma Co., Ltd., and Wilson’s Therapeutics AB.
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share